{"id":5389459619998,"title":"BioCeuticals Clinical UB 75 30caps","handle":"bioceuticals-clinical-ub-75-30-caps","description":"\u003ch2\u003eBioCeuticals Clinical UB 75 30 Caps\u003c\/h2\u003e\n\u003ch3\u003e\u003cem\u003eMulti-strain Probiotic 75 Billion CFU per Capsule\u003c\/em\u003e\u003c\/h3\u003e\n\u003cp\u003eBioCeuticals Clinical UB 75 is part of the BioCeuticals Clinical Range\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBioCeuticals Clinical UB 75 is a combination of 11 probiotic strains providing patients with 75 billion CFU per capsule to maintain normal, healthy intestinal and urogenital flora.\u003c\/li\u003e\n\u003cli\u003eBioCeuticals Clinical UB 75 contains 25 billion of the clinically trialled strains known as LAB4 for symptomatic relief from medically diagnosed irritable bowel syndrome (IBS).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eBioCeuticals Clinical UB 75 a\u003c\/span\u003evailable in sizes: 30 Caps\u003c\/p\u003e\n\u003cp\u003eBioCeuticals Clinical UB 75 is associated with Liver and Detoxification Support, Women's Health, Digestive Health\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBioCeuticals Clinical UB 75 has \u003c\/span\u003eNo Added Dairy, No Added Gluten, Pregnancy Friendly, No Add Shellfish, No added Soy Protein, Vegetarian Friendly, No Added Yeast\u003c\/p\u003e\n\u003c!-- TABS --\u003e\n\u003ch5\u003eDose\u003c\/h5\u003e\n\u003ch2\u003eDose: BioCeuticals Clinical UB 75\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eAdults:\u003c\/strong\u003e Take 1-2 capsules twice daily or as directed by your healthcare practitioner.\u003c\/p\u003e\n\u003ch5\u003eFeatures\u003c\/h5\u003e\n\u003ch2\u003eFeatures: BioCeuticals Clinical UB 75\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eProvides nutritional support for normal healthy intestinal flora.\u003c\/li\u003e\n\u003cli\u003eAids digestion and supports a healthy digestive function, as documented by the International Scientiic Association for Probiotics and Prebiotics (ISAPP).1\u003c\/li\u003e\n\u003cli\u003eProvides the clinically trialled dose of LAB4 probiotics – Lactobacillus acidophilus (CUL 21 + CUL 60), Bifidobacterium bifidum (CUL 20) and B. animalis ssp. Lactis (CUL 34) – for symptomatic relief and management of medically diagnosed IBS.\u003c\/li\u003e\n\u003cli\u003eMay assist in the maintenance of healthy microflora in the urogenital tract.\u003c\/li\u003e\n\u003cli\u003eSupports normal resistance to disease through its role in gut-associated lymphoid tissue (GALT) maturation.\u003c\/li\u003e\n\u003cli\u003eacidophilus is a microorganism that naturally inhabits the bowel, and produces vitamin K, lactase and antimicrobial substances.\u003c\/li\u003e\n\u003cli\u003eDairy free and vegetarian friendly.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch5\u003eIngredient Summary\u003c\/h5\u003e\n\u003ch2\u003eIngredient Summary: BioCeuticals Clinical UB 75\u003c\/h2\u003e\n\u003ch3\u003e\u003cem\u003eLAB4 blend\u003c\/em\u003e\u003c\/h3\u003e\n\u003cp\u003eIBS has been correlated with a lower amount of lactobacilli and bifidobacteria in the gut.2 The altered composition and metabolic activity of the intestinal microbiota may be associated with activation of mucosal immunity and inflammation, suggesting a potential intervention strategy comprising both organisms.3,4\u003c\/p\u003e\n\u003cp\u003eA significant improvement in the symptom severity score of IBS and in scores for quality of life, days with pain and satisfaction with bowel habit compared with the placebo group was observed over the 8-week intervention period using 25 billion CFU of LAB4.3\u003c\/p\u003e\n\u003ch3\u003e\u003cem\u003eUse of lactobacillus probiotics for urogenital infections\u003c\/em\u003e\u003c\/h3\u003e\n\u003cp\u003eLactobacilli, the dominant microorganisms in the urinary tract, may decrease the proliferation and growth of uropathogens through competitive inhibition and the production of antimicrobial compounds.5\u003c\/p\u003e\n\u003cp\u003eL. plantarum appears to possess properties to maintain urogenital health by adhering to the urogenital surface, reducing pH, inhibiting pathogenic microbial growth through hydrogen peroxide production.6\u003c\/p\u003e\n\u003cp\u003eL. fermentum and L. rhamnosus have been clinically demonstrated to resist uropathogen colonisation and assist in the maintenance of healthy urogenital flora.7\u003c\/p\u003e\n\u003ch3\u003e\u003cem\u003eMucosal immune system\u003c\/em\u003e\u003c\/h3\u003e\n\u003cp\u003eThe normal colonic microflora, particularly lactobacilli and bifidobacteria, contribute greatly towards the host’s defence of the gastrointestinal tract by colonisation resistance and interactions with the immune system.8\u003c\/p\u003e\n\u003cp\u003eL. acidophilus and L. casei are demonstrated to adhere to the intestinal mucosa and may block the adherence of enteropathogens.9\u003c\/p\u003e\n\u003cp\u003eL. plantarum is most often associated with bacteriocin production,9 which reduces the survival of competing pathogens.\u003c\/p\u003e\n\u003ch5\u003eIngredients\u003c\/h5\u003e\n\u003ch2\u003eIngredients: BioCeuticals Clinical UB 75\u003c\/h2\u003e\n\u003ctable width='100%\"'\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eEach capsule contains:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLactobacillus acidophilus (CUL 21 + CUL 60)\u003c\/td\u003e\n\u003ctd\u003e20 billion CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLactobacillus rhamnosus (CUL 63)\u003c\/td\u003e\n\u003ctd\u003e15.55 billion CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLactobacillus gasseri (Lg-36)\u003c\/td\u003e\n\u003ctd\u003e15 billion CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLactobacillus casei (CUL 07)\u003c\/td\u003e\n\u003ctd\u003e9.45 billion CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLactobacillus plantarum (CUL 66)\u003c\/td\u003e\n\u003ctd\u003e3.15 billion CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLactobacillus fermentum (CUL 67)\u003c\/td\u003e\n\u003ctd\u003e1.35 billion CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBifidobacterium animalis ssp. lactis (CUL 34)\u003c\/td\u003e\n\u003ctd\u003e6.55 billion CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBifidobacterium breve (CUL 69)\u003c\/td\u003e\n\u003ctd\u003e1.35 billion CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBifidobacterium biidum (CUL 20)\u003c\/td\u003e\n\u003ctd\u003e345 million CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStreptococcus thermophilus (CUL 68)\u003c\/td\u003e\n\u003ctd\u003e2.25 billion CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch5\u003eFree From\u003c\/h5\u003e\n\u003ch2\u003eFree From: BioCeuticals Clinical UB 75\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eNo Added Dairy\u003c\/li\u003e\n\u003cli\u003eNo Added Gluten\u003c\/li\u003e\n\u003cli\u003ePregnancy Friendly\u003c\/li\u003e\n\u003cli\u003eNo Add Shellfish\u003c\/li\u003e\n\u003cli\u003eNo added Soy Protein\u003c\/li\u003e\n\u003cli\u003eVegetarian Friendly\u003c\/li\u003e\n\u003cli\u003eNo Added Yeast\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch5\u003eReferences\u003c\/h5\u003e\n\u003ch2\u003eReferences: BioCeuticals Clinical UB 75\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eHill C, Guarner F, Reid G, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506-514.\u003c\/li\u003e\n\u003cli\u003eRitchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS ONE 2012;7(4):e34938.\u003c\/li\u003e\n\u003cli\u003eWilliams EA, Stimpson J, Wang D, et al. Clinical trial: a multi-strain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 2008;29:97-103.\u003c\/li\u003e\n\u003cli\u003eLee KN, Lee OY. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol 2014;20(27):8886-8897.\u003c\/li\u003e\n\u003cli\u003eBarrons R, Tassone, D. Use of lactobacillus probiotics for bacterial genitourinary infections in women: a review. Clin Ther 2008;30(3):453-468.\u003c\/li\u003e\n\u003cli\u003eRönnqvist D, Ström H, Forsgren-Brusk U, et al. Selection and characterization of a Lactobacillus plantarum strain promising as a urogenital probiotic. Microbial Ecol Health Dis 2005;17:75-82.\u003c\/li\u003e\n\u003cli\u003eReid G, Burton J, Devillard, E. The rationale for probiotics in female urogenital healthcare. MedGenMed 2004;6(1):49.\u003c\/li\u003e\n\u003cli\u003eMacfarlane GT, Cummings JH. Probiotics, infection and immunity. Curr Opin Infect Dis 2002;15:501-506.\u003c\/li\u003e\n\u003cli\u003eFooks LJ, Gibson, GR. Probiotics as modulators of the gut flora. Br J Nutr 2002;88(Suppl 1):S39-49.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c!-- \/TABS --\u003e","published_at":"2022-10-11T14:05:50+11:00","created_at":"2020-07-07T17:59:26+10:00","vendor":"BioCeuticals","type":"BioCeuticals Clinical Naturopathic Medicines","tags":["BioCeuticals Clinical","Naturopathic","PB"],"price":6476,"price_min":6476,"price_max":6476,"available":true,"price_varies":false,"compare_at_price":7195,"compare_at_price_min":7195,"compare_at_price_max":7195,"compare_at_price_varies":false,"variants":[{"id":34962077319326,"title":"Default Title","option1":"Default Title","option2":null,"option3":null,"sku":"BiCClUB7530C","requires_shipping":true,"taxable":true,"featured_image":null,"available":true,"name":"BioCeuticals Clinical UB 75 30caps","public_title":null,"options":["Default Title"],"price":6476,"weight":120,"compare_at_price":7195,"inventory_quantity":9893,"inventory_management":"shopify","inventory_policy":"continue","barcode":"9337896017043","requires_selling_plan":false,"selling_plan_allocations":[]}],"images":["\/\/shop.healthmasters.com.au\/cdn\/shop\/products\/BioCeuticalsUB7530Caps10_offRRPatHealthMastersBioCeuticals.jpg?v=1609636226","\/\/shop.healthmasters.com.au\/cdn\/shop\/products\/BioCeuticalsUB7530Caps-pill10_offRRPatHealthMastersBioCeuticals.jpg?v=1609636249","\/\/shop.healthmasters.com.au\/cdn\/shop\/products\/BioCeuticalsClinical10_offRRPatBioCeuticalsClinical_88fe93fa-2812-48ea-8cce-4ab5fe75f19d.jpg?v=1609733672"],"featured_image":"\/\/shop.healthmasters.com.au\/cdn\/shop\/products\/BioCeuticalsUB7530Caps10_offRRPatHealthMastersBioCeuticals.jpg?v=1609636226","options":["Title"],"media":[{"alt":"BioCeuticals Clinical UB 75 30 Caps 10% off RRP at HealthMasters BioCeuticals Clinical","id":9946416251038,"position":1,"preview_image":{"aspect_ratio":0.461,"height":1200,"width":553,"src":"\/\/shop.healthmasters.com.au\/cdn\/shop\/products\/BioCeuticalsUB7530Caps10_offRRPatHealthMastersBioCeuticals.jpg?v=1609636226"},"aspect_ratio":0.461,"height":1200,"media_type":"image","src":"\/\/shop.healthmasters.com.au\/cdn\/shop\/products\/BioCeuticalsUB7530Caps10_offRRPatHealthMastersBioCeuticals.jpg?v=1609636226","width":553},{"alt":"BioCeuticals Clinical UB 75 30 Caps-pill 10% off RRP at HealthMasters BioCeuticals Clinical","id":9946416283806,"position":2,"preview_image":{"aspect_ratio":1.556,"height":90,"width":140,"src":"\/\/shop.healthmasters.com.au\/cdn\/shop\/products\/BioCeuticalsUB7530Caps-pill10_offRRPatHealthMastersBioCeuticals.jpg?v=1609636249"},"aspect_ratio":1.556,"height":90,"media_type":"image","src":"\/\/shop.healthmasters.com.au\/cdn\/shop\/products\/BioCeuticalsUB7530Caps-pill10_offRRPatHealthMastersBioCeuticals.jpg?v=1609636249","width":140},{"alt":"BioCeuticals Clinical 10% off RRP at BioCeuticals Clinical","id":12991560974494,"position":3,"preview_image":{"aspect_ratio":1.608,"height":120,"width":193,"src":"\/\/shop.healthmasters.com.au\/cdn\/shop\/products\/BioCeuticalsClinical10_offRRPatBioCeuticalsClinical_88fe93fa-2812-48ea-8cce-4ab5fe75f19d.jpg?v=1609733672"},"aspect_ratio":1.608,"height":120,"media_type":"image","src":"\/\/shop.healthmasters.com.au\/cdn\/shop\/products\/BioCeuticalsClinical10_offRRPatBioCeuticalsClinical_88fe93fa-2812-48ea-8cce-4ab5fe75f19d.jpg?v=1609733672","width":193}],"requires_selling_plan":false,"selling_plan_groups":[],"content":"\u003ch2\u003eBioCeuticals Clinical UB 75 30 Caps\u003c\/h2\u003e\n\u003ch3\u003e\u003cem\u003eMulti-strain Probiotic 75 Billion CFU per Capsule\u003c\/em\u003e\u003c\/h3\u003e\n\u003cp\u003eBioCeuticals Clinical UB 75 is part of the BioCeuticals Clinical Range\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBioCeuticals Clinical UB 75 is a combination of 11 probiotic strains providing patients with 75 billion CFU per capsule to maintain normal, healthy intestinal and urogenital flora.\u003c\/li\u003e\n\u003cli\u003eBioCeuticals Clinical UB 75 contains 25 billion of the clinically trialled strains known as LAB4 for symptomatic relief from medically diagnosed irritable bowel syndrome (IBS).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan\u003eBioCeuticals Clinical UB 75 a\u003c\/span\u003evailable in sizes: 30 Caps\u003c\/p\u003e\n\u003cp\u003eBioCeuticals Clinical UB 75 is associated with Liver and Detoxification Support, Women's Health, Digestive Health\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003eBioCeuticals Clinical UB 75 has \u003c\/span\u003eNo Added Dairy, No Added Gluten, Pregnancy Friendly, No Add Shellfish, No added Soy Protein, Vegetarian Friendly, No Added Yeast\u003c\/p\u003e\n\u003c!-- TABS --\u003e\n\u003ch5\u003eDose\u003c\/h5\u003e\n\u003ch2\u003eDose: BioCeuticals Clinical UB 75\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eAdults:\u003c\/strong\u003e Take 1-2 capsules twice daily or as directed by your healthcare practitioner.\u003c\/p\u003e\n\u003ch5\u003eFeatures\u003c\/h5\u003e\n\u003ch2\u003eFeatures: BioCeuticals Clinical UB 75\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eProvides nutritional support for normal healthy intestinal flora.\u003c\/li\u003e\n\u003cli\u003eAids digestion and supports a healthy digestive function, as documented by the International Scientiic Association for Probiotics and Prebiotics (ISAPP).1\u003c\/li\u003e\n\u003cli\u003eProvides the clinically trialled dose of LAB4 probiotics – Lactobacillus acidophilus (CUL 21 + CUL 60), Bifidobacterium bifidum (CUL 20) and B. animalis ssp. Lactis (CUL 34) – for symptomatic relief and management of medically diagnosed IBS.\u003c\/li\u003e\n\u003cli\u003eMay assist in the maintenance of healthy microflora in the urogenital tract.\u003c\/li\u003e\n\u003cli\u003eSupports normal resistance to disease through its role in gut-associated lymphoid tissue (GALT) maturation.\u003c\/li\u003e\n\u003cli\u003eacidophilus is a microorganism that naturally inhabits the bowel, and produces vitamin K, lactase and antimicrobial substances.\u003c\/li\u003e\n\u003cli\u003eDairy free and vegetarian friendly.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch5\u003eIngredient Summary\u003c\/h5\u003e\n\u003ch2\u003eIngredient Summary: BioCeuticals Clinical UB 75\u003c\/h2\u003e\n\u003ch3\u003e\u003cem\u003eLAB4 blend\u003c\/em\u003e\u003c\/h3\u003e\n\u003cp\u003eIBS has been correlated with a lower amount of lactobacilli and bifidobacteria in the gut.2 The altered composition and metabolic activity of the intestinal microbiota may be associated with activation of mucosal immunity and inflammation, suggesting a potential intervention strategy comprising both organisms.3,4\u003c\/p\u003e\n\u003cp\u003eA significant improvement in the symptom severity score of IBS and in scores for quality of life, days with pain and satisfaction with bowel habit compared with the placebo group was observed over the 8-week intervention period using 25 billion CFU of LAB4.3\u003c\/p\u003e\n\u003ch3\u003e\u003cem\u003eUse of lactobacillus probiotics for urogenital infections\u003c\/em\u003e\u003c\/h3\u003e\n\u003cp\u003eLactobacilli, the dominant microorganisms in the urinary tract, may decrease the proliferation and growth of uropathogens through competitive inhibition and the production of antimicrobial compounds.5\u003c\/p\u003e\n\u003cp\u003eL. plantarum appears to possess properties to maintain urogenital health by adhering to the urogenital surface, reducing pH, inhibiting pathogenic microbial growth through hydrogen peroxide production.6\u003c\/p\u003e\n\u003cp\u003eL. fermentum and L. rhamnosus have been clinically demonstrated to resist uropathogen colonisation and assist in the maintenance of healthy urogenital flora.7\u003c\/p\u003e\n\u003ch3\u003e\u003cem\u003eMucosal immune system\u003c\/em\u003e\u003c\/h3\u003e\n\u003cp\u003eThe normal colonic microflora, particularly lactobacilli and bifidobacteria, contribute greatly towards the host’s defence of the gastrointestinal tract by colonisation resistance and interactions with the immune system.8\u003c\/p\u003e\n\u003cp\u003eL. acidophilus and L. casei are demonstrated to adhere to the intestinal mucosa and may block the adherence of enteropathogens.9\u003c\/p\u003e\n\u003cp\u003eL. plantarum is most often associated with bacteriocin production,9 which reduces the survival of competing pathogens.\u003c\/p\u003e\n\u003ch5\u003eIngredients\u003c\/h5\u003e\n\u003ch2\u003eIngredients: BioCeuticals Clinical UB 75\u003c\/h2\u003e\n\u003ctable width='100%\"'\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eEach capsule contains:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLactobacillus acidophilus (CUL 21 + CUL 60)\u003c\/td\u003e\n\u003ctd\u003e20 billion CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLactobacillus rhamnosus (CUL 63)\u003c\/td\u003e\n\u003ctd\u003e15.55 billion CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLactobacillus gasseri (Lg-36)\u003c\/td\u003e\n\u003ctd\u003e15 billion CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLactobacillus casei (CUL 07)\u003c\/td\u003e\n\u003ctd\u003e9.45 billion CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLactobacillus plantarum (CUL 66)\u003c\/td\u003e\n\u003ctd\u003e3.15 billion CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLactobacillus fermentum (CUL 67)\u003c\/td\u003e\n\u003ctd\u003e1.35 billion CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBifidobacterium animalis ssp. lactis (CUL 34)\u003c\/td\u003e\n\u003ctd\u003e6.55 billion CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBifidobacterium breve (CUL 69)\u003c\/td\u003e\n\u003ctd\u003e1.35 billion CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBifidobacterium biidum (CUL 20)\u003c\/td\u003e\n\u003ctd\u003e345 million CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStreptococcus thermophilus (CUL 68)\u003c\/td\u003e\n\u003ctd\u003e2.25 billion CFU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch5\u003eFree From\u003c\/h5\u003e\n\u003ch2\u003eFree From: BioCeuticals Clinical UB 75\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eNo Added Dairy\u003c\/li\u003e\n\u003cli\u003eNo Added Gluten\u003c\/li\u003e\n\u003cli\u003ePregnancy Friendly\u003c\/li\u003e\n\u003cli\u003eNo Add Shellfish\u003c\/li\u003e\n\u003cli\u003eNo added Soy Protein\u003c\/li\u003e\n\u003cli\u003eVegetarian Friendly\u003c\/li\u003e\n\u003cli\u003eNo Added Yeast\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch5\u003eReferences\u003c\/h5\u003e\n\u003ch2\u003eReferences: BioCeuticals Clinical UB 75\u003c\/h2\u003e\n\u003col\u003e\n\u003cli\u003eHill C, Guarner F, Reid G, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506-514.\u003c\/li\u003e\n\u003cli\u003eRitchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS ONE 2012;7(4):e34938.\u003c\/li\u003e\n\u003cli\u003eWilliams EA, Stimpson J, Wang D, et al. Clinical trial: a multi-strain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 2008;29:97-103.\u003c\/li\u003e\n\u003cli\u003eLee KN, Lee OY. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol 2014;20(27):8886-8897.\u003c\/li\u003e\n\u003cli\u003eBarrons R, Tassone, D. Use of lactobacillus probiotics for bacterial genitourinary infections in women: a review. Clin Ther 2008;30(3):453-468.\u003c\/li\u003e\n\u003cli\u003eRönnqvist D, Ström H, Forsgren-Brusk U, et al. Selection and characterization of a Lactobacillus plantarum strain promising as a urogenital probiotic. Microbial Ecol Health Dis 2005;17:75-82.\u003c\/li\u003e\n\u003cli\u003eReid G, Burton J, Devillard, E. The rationale for probiotics in female urogenital healthcare. MedGenMed 2004;6(1):49.\u003c\/li\u003e\n\u003cli\u003eMacfarlane GT, Cummings JH. Probiotics, infection and immunity. Curr Opin Infect Dis 2002;15:501-506.\u003c\/li\u003e\n\u003cli\u003eFooks LJ, Gibson, GR. Probiotics as modulators of the gut flora. Br J Nutr 2002;88(Suppl 1):S39-49.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c!-- \/TABS --\u003e"}